Recombinant Anti-IDH1 Anticorps [IDH1.R132H/7277R] (A315129)

Anti-IDH1 Antibody [IDH1.R132H/7277R]

Recombinant rabbit monoclonal [IDH1.R132H/7277R] antibody to IDH1.

IDH1 R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.

IHC-P

HepG2, HeLa, HT29 or MCF7 cells. Human breast, colon or prostate carcinoma.

IHC: 1-2 µg/ml

Human

Recombinant fragment of human IDH1. The exact sequence is proprietary.

Rabbit

Monoclonal

IDH1.R132H/7277R

IgG

Unconjugated

Protein A/G chromatography.

200 µg/ml

45-47 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Cytosolic NADP isocitrate dehydrogenase, Cytosolic NADP-isocitrate dehydrogenase, Epididymis luminal protein 216, Epididymis secretory protein Li 26, HEL-216, HEL-S-26, ICDH, IDCD, IDH, IDHC_HUMAN, IDP, IDPC, Isocitrate dehydrogenase, Isocitrate dehydrogenase (NADP(+)) 1 cytosolic, Isocitrate dehydrogenase 1 (NADP+) soluble, Isocitrate dehydrogenase [NADP] cytoplasmic, NADP dependent isocitrate dehydrogenase cytosolic, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, PICD